Nycomed resolute on pursuing damages from Teva, Sun over generic Protonix
This article was originally published in Scrip
Executive Summary
Swiss firm Nycomed, which has been hit by at-risk launches of generic versions of Protonix (pantoprazole) by Teva Pharmaceutical Industries and Sun Pharma in the US, appears determined to pursue damage claims against the two firms, leaving little hope for the possibility of a settlement with them prior to the expiry of the Protonix patent next year.